Efficacy of subcutaneous injection of platelet-rich plasma in alopecia: A clinical and histological pilot study on a rat model with a six-month long-term follow-up experience

2017 ◽  
Vol 17 (2) ◽  
pp. 214-219 ◽  
Author(s):  
Sophie Orliac ◽  
Jean-Michel Serfaty ◽  
Anne Perozziello ◽  
Olivier Zurlinden ◽  
Liliane Louedec ◽  
...  
2006 ◽  
Vol 6 (5) ◽  
pp. 6S-7S
Author(s):  
Alexander Vaccaro ◽  
D. Greg Anderson ◽  
Tushar Patel ◽  
Jeffrey Fischgrund ◽  
Eeric Truumees ◽  
...  

2015 ◽  
Vol 11 (11) ◽  
pp. 1273-1279 ◽  
Author(s):  
Ambra Stefani ◽  
David Gabelia ◽  
Birgit Högl ◽  
Thomas Mitterling ◽  
Philipp Mahlknecht ◽  
...  

2013 ◽  
Vol 144 (5) ◽  
pp. S-173 ◽  
Author(s):  
Miguel Regueiro ◽  
Leonard Baidoo ◽  
Kevin E. Kip ◽  
Jason M. Swoger ◽  
David G. Binion ◽  
...  

1983 ◽  
Vol 91 (4) ◽  
pp. 437-440 ◽  
Author(s):  
Steven D. Handler ◽  
William P. Potsic ◽  
Roger R. Marsh

A prospective controlled pilot study was undertaken in which Biolite (carbon-coated) ventilation tubes were placed in 44 ears and a conventional silicone tube in the contralateral ear. Long-term follow-up of these patients has revealed little difference in the incidence of tube occlusion or early extrusion. In addition, there were several disadvantages noted with the Biolite tubes: incomplete coating of the tube (especially within the lumen), shedding of the Biolite coating over time, “tattooing” of the tympanic membrane, poor otoscopic visibility, and the higher cost of these tubes. Since the Biolite tube has no documented advantages and, actually, several disadvantages, we believe its use in the treatment of middle ear disorders should be discontinued until significant benefits are demonstrated and present deficiencies are corrected.


2011 ◽  
Vol 118 (5) ◽  
pp. 765-772 ◽  
Author(s):  
Melita Salkovic-Petrisic ◽  
Jelena Osmanovic-Barilar ◽  
Martina K. Brückner ◽  
Siegfried Hoyer ◽  
Thomas Arendt ◽  
...  

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 60-60
Author(s):  
Noelia Sanmamed ◽  
Rachel Glicksman ◽  
John Thoms ◽  
Alexandre Zlotta ◽  
Antonio Finelli ◽  
...  

60 Background: Pre-operative radiotherapy (PreORT) improves local control in various cancer types, and has become an established oncologic treatment strategy. During 2001-2004, we conducted a phase I pilot study assessing the role of short-course PreORT for men with unfavourable intermediate- and high-risk localized prostate cancer (PCa). We present long-term follow-up toxicity and oncologic outcomes. Methods: Eligible patients had histologically proven PCa, cT1-T2N0M0, PSA > 15-35 ng/ml with any Gleason score, or PSA 10-15 ng/ml with Gleason score ≥7. Patients received 25 Gy in five consecutive daily fractions to the prostate, followed by radical prostatectomy (RadP) within 14 days after RT completion. Primary outcomes were intra-operative morbidity, and late genitourinary (GU) and gastrointestinal (GI) toxicities. Acute toxicity was assessed during radiotherapy treatment on daily basis using RTOG grade scoring scale. Patients were assessed post-RadP clinically and with PSA at 1 and 6 months, and every 6 months. Intra- and Post-RadP toxicity was documented prospectively and scored as per Common Terminology Criteria for Adverse Events v4.0. Biochemical failure (BF) was determined based on two consecutive post-RadP PSA > 0.2 ng/ml. Results: Fifteen patients were enrolled; 14 patients completed PreORT followed by RadP, which also included bilateral lymph node dissections in 13 cases. Median follow-up was 12.2 years (range 6.7-16.3 years). Late GU toxicity was common, with 2 patients (14.3%) experiencing G2 toxicity, and 6 patients (42.8%) G3 toxicity. There were no G4-5 late GU toxicity. Late GI toxicity was infrequent, with only 1 patient (7.1%) experiencing transient G2 proctitis. At last follow-up, 8 (57.1%) and 6 (42.8%) patients experienced BF and metastatic disease recurrence, respectively. Conclusions: The use of PreORT in men with high-risk PCa is associated with unexpected high-rates of late GU toxicity. Future studies examining the role of RT pre-RadP must cautiously select RT technique and dose schedule. Importantly, long-term follow-up data is essential to fully determine the therapeutic index of PreORT in the management of localized PCa. Clinical trial information: NCT00252447.


2019 ◽  
Vol 25 (10) ◽  
pp. 1965-1969 ◽  
Author(s):  
Behnam Sadeghi ◽  
Mats Remberger ◽  
Britt Gustafsson ◽  
Jacek Winiarski ◽  
Gianluca Moretti ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document